Compare Gartner Inc (IT) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gartner Inc vs Pfizer Inc — how do they compare? Gartner Inc trades at $191.23 (market cap $12.34B), while Pfizer Inc trades at $28.06 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 12.8× Gartner Inc's market cap, and Pfizer Inc pays a 6.18% dividend while Gartner Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gartner Inc for 64 Days and Pfizer Inc for 158 Days on average.
| IT | PFE | |
|---|---|---|
Market Cap | $12.34B | $158.56B |
Volume | 919,809 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $258.17 | $29.02 |
52-Week Low | $125.68 | $23.67 |
Typical Hold Time | 64 Days | 158 Days |
Enterprise Value | $14.08B | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gartner (IT) trades at $195.09, up 5.02% today, showing strong momentum with three consecutive quarterly EPS beats. The stock exhibits bullish technical signals with support at $185 and resistance at $188. Fundamentally, the company maintains robust profitability with 69.63% gross margins and 12% net income margin, though 2025 net income declined to $729M from 2024's $1.3B. Recent news highlights AI advisory demand growth and the upcoming Gartner IT Symposium in October.
Outlook remains positive with analyst consensus at Buy (28%) and $174.63 price target, though current price exceeds target. Key opportunities include strong ROE (113.58%) and AI-driven consulting demand. Risks include negative cash flow trends (-$211M in 2025) and potential fiduciary investigation noted in recent filings. Institutional sentiment appears mixed with 56% Hold ratings.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gartner Inc
Based in Stamford, Conn., Gartner provides independent research and analysis on information technology and other related technology industries. Its research is delivered to clients' desktops in the form of reports, briefings, and updates. Typical clients are chief information officers and other business executives who help plan companies' IT budgets. Gartner also provides consulting services and hosted nearly 80 IT conferences across the globe in 2007.
Read more on IT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
